On Aug. 24 2020, NantKwest and ImmunityBio announced an agreement to jointly develop, manufacture, market, and commercialize therapeutics and vaccines for combating the COVID-19 pandemic.

The two companies agreed to share equally the costs incurred after August 21, 2020 of development, manufacturing, marketing, and commercialization of the products each is developing related to COVID-19.